Stocks Health care JSPR
NASDAQ · Health careJasper Therapeutics, Inc. (JSPR)
It posted a net loss of $31.8M. At June 30, 2026 it held $7.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Jasper Therapeutics, Inc. does
Jasper Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker JSPR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$75.8M | -$3.95 | n/a |
| 2024 | n/a | -$71.3M | -$4.89 | n/a |
| 2023 | n/a | -$64.5M | -$6.18 | n/a |
| 2022 | n/a | -$37.7M | -$10.33 | n/a |
| 2021 | n/a | -$30.6M | -$26.98 | n/a |
| 2020 | n/a | -$31.7M | -$51.85 | n/a |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Jasper Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026Delisting notice 25-NSE
- September 4, 2026Proxy statement DEF 14A
- August 26, 2026
- August 24, 2026Preliminary proxy statement PRE 14A
- August 17, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026
- August 14, 2026
- August 3, 2026
- July 31, 2026Other event 8-K
- July 20, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Jasper Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns JSPR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Velan Capital Investment Management LP13G, passive with 11 related filers | 9.9% | August 17, 2026 |
| T. Rowe Price Investment Management, Inc.13G, passive | 7.1% | November 14, 2025 |
| Anders Hove13G, passive with 4 related filers | 5.3% | January 26, 2026 |
Largest institutional holders
Insiders
Questions about JSPR
What does Jasper Therapeutics, Inc. do?
Jasper Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker JSPR.
Is Jasper Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $31.8M.
When did Jasper Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the delisting notice from September 24, 2026.
Similar companies
Compare JSPR with
Follow JSPR
Get an email when Jasper Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow JSPR: get an email when it filesWhere the numbers come from
Financial figures are the values Jasper Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.